Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 9/20 | 0.54 |
| ▸ | BCR | P11274 | 5/20 | 0.54 |
| ▸ | NR2E1 | Q9Y466 | 3/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.52 |
| ▸ | BRAF | P15056 | 3/20 | 0.52 |
| ▸ | RAF1 | P04049 | 2/20 | 0.52 |
| ▸ | LDLR | P01130 | 3/20 | 0.51 |
| ▸ | KIT | P10721 | 3/20 | 0.51 |
| ▸ | PCSK9 | Q8NBP7 | 3/20 | 0.51 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.48 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.47 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.47 |
| ▸ | STK10 | O94804 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1077857 | 0.88 | LCK (0.58) | ABL1MAPK14BRAFRAF1KIT | |
| SCHEMBL1078917 | 0.88 | ABL1 (0.58) | ABL1BCRNR2E1MAPK14MAP3K20 | |
| SCHEMBL1149298 | 0.85 | ABL1 (0.47) | ABL1BCRMAPK14BRAFRAF1 | |
| SCHEMBL1149686 | 0.83 | LCK (0.58) | ABL1MAPK14BRAFRAF1KIT | |
| SCHEMBL1082897 | 0.82 | LCK (0.55) | ABL1MAPK14BRAFRAF1KIT | |
| SCHEMBL1149152 | 0.82 | LCK (0.53) | ABL1BCRMAPK14BRAFRAF1 | |
| SCHEMBL1077386 | 0.80 | KDR (0.53) | ABL1MAPK14BRAFSRCLCK | |
| SCHEMBL1149223 | 0.80 | DDR2 (0.57) | MAPK14BRAFRAF1KITSRC | |
| SCHEMBL1083503 | 0.80 | LCK (0.48) | MAPK14BRAFSRCLCKTEK | |
| SCHEMBL1149173 | 0.80 | KDR (0.54) | MAPK14BRAFLCKTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2269993-B1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-02-27 | — | — | EP | disclosed |
| US-20110039845-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-02-17 | — | — | US | disclosed |
| EP-2269993-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039845-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | H1-2, H1-3, H1-0 | ABL1 47/4885BCR 3233/4885NR2E1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.